Keros Therapeutics Inc is a biotechnology company focused on developing innovative therapies to treat rare hematological and muscle disorders
The company is dedicated to advancing its proprietary drug candidates that target the transforming growth factor beta (TGF-β) superfamily, which plays a critical role in various cellular processes, including muscle and blood formation. By leveraging their expertise in molecular biology and drug development, Keros Therapeutics aims to provide new treatment options for patients with unmet medical needs while fostering advancements in the understanding of these complex diseases.
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target.
Shares of Mobileye Global Inc. (NASDAQMBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSELW) rose during Thursday’s session following better-than-expected quarterly results.
Shares of bluebird bio, Inc. (NASDAQBLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session.
